3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Lymphoma
2
Recurrence
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Diarrhea
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Breast Neoplasms
1
Interventions
Rituximab
45
Cyclophosphamide
34
Doxorubicin
16
fludarabine
14
Prednisone
14
Vincristine
13
Etoposide
13
ibrutinib
10
Mycophenolic Acid
8
Bortezomib
8
Magnetic Resonance Spectroscopy
7
Lenalidomide
7
Cytarabine
7
pembrolizumab
6
Immunotherapy, Adoptive
6
polatuzumab vedotin
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vorinostat
5
Tacrolimus
5
Specimen Handling
5
CT-P10
5
obinutuzumab
4
ibritumomab tiuxetan
4
Nivolumab
4
Ifosfamide
4
Carmustine
4
Carboplatin
4
Antilymphocyte Serum
4
tafasitamab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, B-Cell
×
Drugs, Investigational
×
Clear all
NCT05972720
2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2
Terminated
101 enrolled